Overview

Pharmacologic Effects of Darifenacin and Tolterodine on Cardiovascular Parameters in Healthy Subjects

Status:
Completed
Trial end date:
2007-09-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the pharmacologic effects of exposure to darifenacin and tolterodine on cardiovascular parameters in healthy subjects 50 years of age and older
Phase:
Phase 4
Details
Lead Sponsor:
Novartis
Collaborator:
Procter and Gamble
Treatments:
Darifenacin
Tolterodine Tartrate